BofA cuts Doximity stock price target on transition year outlook By Investing.com

BofA Securities cut its price target on Doximity to $47 from $56 but kept a Buy rating, citing a mixed yet ultimately positive quarter with firmer digital budgets and share gains. The firm highlighted valuation support from an 89.75% gross margin and a 0.94 PEG ratio, while noting FY2027 will be a transition year as DoxGPT incurs costs before meaningful revenue. Recent analyst views remain mixed, with Evercore downgrading to In Line and Piper Sandler raising its target to $42.

Analysis

The market is still treating DOCS as a simple multiple compression story, but the more important setup is that the bear case is shifting from demand destruction to product monetization risk. If digital ad/engagement budgets are holding up while competitive noise from OpenEvidence is contained, the near-term issue becomes whether Doximity can convert usage into paid workflow penetration before the AI feature cycle turns into a cost drag. That creates a classic “good-enough fundamentals, bad timing” tape: the stock can re-rate higher on evidence of retention, but any delay in AI monetization likely caps upside into the next few quarters.

Second-order, the AI angle may help competitors more than Doximity if buyers use it as a feature benchmark rather than a standalone moat. In healthcare software, incumbents often lose margin first when they have to defend share with product giveaways or bundled AI tools; the risk is not revenue collapse, but lower incremental profitability that keeps the multiple from recovering. That makes the next two earnings cycles more important than the full-year narrative, because investors will focus on gross margin durability and sales efficiency rather than TAM rhetoric.

The contrarian view is that the selloff may be overdone relative to the company’s underlying operating leverage. At current levels, the market is implicitly pricing in either a prolonged slowdown or a meaningful competitive share loss, yet the setup appears more like an inflection in expectations: if budgets stay firm and share gains continue, even modest upside revisions can drive a sharp short-covering move. The key tell is whether management frames AI as a retention and upsell tool versus a costly experiment; the latter would justify caution, while the former could re-rate the name over 6-12 months.

Key Decisions for Investors

• Go long DOCS on a 3-6 month horizon only on post-print confirmation of budget stability and retention metrics; risk/reward improves if the stock trades below the lower end of recent analyst targets, with upside to a sentiment-driven squeeze if the company avoids margin compression.
• Buy DOCS call spreads 3-6 months out to express a rebound in valuation while capping premium at risk; this is best if you expect multiple expansion from a beats-and-raises setup rather than fundamental acceleration.
• Pair trade: long DOCS / short a higher-multiple healthcare software peer with more AI narrative risk over the next 1-2 quarters; the thesis is that DOCS has a lower bar to re-rate if execution stabilizes while the short leg absorbs any sector de-rating.
• Do not add aggressively ahead of evidence on DoxGPT monetization; if the next update shows rising AI costs without revenue contribution, cut exposure quickly because the market will likely re-price the stock lower on margin fears.
• For tactical traders, consider waiting for a sell-the-news reaction to analyst upgrades before entering long exposure; the best entry is likely on a 1-2 day pullback after enthusiasm fades rather than chasing momentum.